The collaboration with Voyager Therapeutics is likely to be viewed positively by investors as it strengthens Novartis's position in the gene therapy market, particularly for Huntington's disease and spinal muscular atrophy, which are areas with significant unmet medical needs. This strategic move could lead to long-term growth and value creation, thus the short-term positive impact on NVS stock.